- $3.57bn
- $3.08bn
- $517.15m
Veracyte Inc reports results for the quarter ended in March - Earnings Summary
Brief: Veracyte Q1 Revenue USD 96.8 Million Vs. IBES Estimate USD 93.4 Million
Veracyte Inc expected to post a loss of 18 cents a share - Earnings Preview
Brief: Veracyte Selling Stockholders May Offer And Resell Up To 1.7 Mln Shares Of Common Stock Under The Prospectus Supplement
U.S. RESEARCH ROUNDUP-Agiliti, Domino's Pizza, Krystal Biotech
Veracyte Inc reports results for the quarter ended in December - Earnings Summary
Brief: Veracyte Q4 Revenue USD 98.2 Million Vs. IBES Estimate USD 92 Million
Brief: Veracyte Completes Acquisition Of C2i Genomics
Brief: Veracyte Announces Prelim Full-Year 2023 Results,
Brief: Veracyte Outlook FY Revenue USD 358-359 Million
Brief: Veracyte Q3 Revenue USD 90.1 Million Vs. IBES Estimate USD 84.4 Million
Veracyte Inc expected to post a loss of 15 cents a share - Earnings Preview
Brief: New Data From Phase 3 Trial Further Validate Prognostic Value Of Veracyte’S Decipher Prostate Genomic Classifier
Veracyte Inc reports results for the quarter ended in June - Earnings Summary
Brief: Veracyte Q2 Revenue USD 90.3 Million Vs. IBES Estimate USD 83.1 Million
Veracyte Inc expected to post a loss of 15 cents a share - Earnings Preview
Brief: Veracyte Says New Data Show Use Of The Prosigna Test Significantly Changed Treatment Decisions For Patients With Early-Stage Breast Cancer
Brief: Veracyte sees FY revenue USD 330-340 million
Veracyte Inc reports results for the quarter ended in March - Earnings Summary